Research programme: ghrelin receptor antagonists - AEterna Zentaris

Drug Profile

Research programme: ghrelin receptor antagonists - AEterna Zentaris

Alternative Names: 1,2,4-Triazole based ghrelin receptor ligands as anti-obesity agents - AEterna Zentaris; AEZS-123; JMV 2760; JMV 2959; JMV 3018; JMV 3534

Latest Information Update: 14 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zentaris
  • Developer AEterna Zentaris GmbH; AEterna Zentaris Inc; University of Milan; University of Montpellier I; University of Montpellier II; University of Montreal
  • Class Small molecules; Triazoles
  • Mechanism of Action Ghrelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Obesity
  • No development reported Alcoholism

Most Recent Events

  • 14 May 2012 AEZS 123 is still in Preclinical trials for Obesity in Canada and Europe
  • 14 May 2012 No development reported - Preclinical for Alcoholism in Canada (unspecified route)
  • 07 Jul 2009 Pharmacodynamics data from a preclinical trial in Alcoholism released by AEterna Zentaris
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top